Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) has taken a significant step toward expanding its oncology portfolio by entering into a non-binding letter of intent (LOI) with Ifowonco Informatics Incorporated. The LOI is the initial step toward negotiating a definitive agreement that, if completed, would grant Onco an exclusive option relating to Ifowonco's proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 (LAG-3). This move signals Onco's intention to strengthen its position in the rapidly evolving field of cancer immunotherapy.
The proposed collaboration is designed to combine Ifowonco's oral small-molecule immune checkpoint technology with Onco-Innovations' expertise in DNA damage response (DDR) therapeutics, translational oncology, and clinical development. The companies believe that the combination of DDR inhibition and LAG-3 blockade could potentially enhance anti-tumour immune responses across multiple solid tumour indications. This is particularly relevant as the field moves toward more targeted and combination approaches to overcome resistance to existing therapies.
Ifowonco's program is focused on developing orally available small-molecule LAG-3 inhibitors, which contrasts with currently approved LAG-3 therapies that are administered intravenously as monoclonal antibodies. Oral small-molecule inhibitors offer potential advantages in terms of patient convenience, manufacturing scalability, and the ability to penetrate tissues more effectively. The companies intend to evaluate the LAG-3 program independently and, where supported by preclinical findings, explore its potential use alongside DDR-based therapeutic approaches, including Onco-Innovations' ONC010 program.
Thomas O'Shaughnessy, CEO of Onco-Innovations, commented on the potential agreement, stating that it could position the company "at the intersection of precision oncology and next-generation cancer immunotherapy." This strategic move aligns with the broader industry trend of combining different mechanisms of action to improve treatment outcomes. The integration of DDR inhibitors with immune checkpoint inhibitors is a promising area of research, as DDR inhibition can increase tumour immunogenicity and potentially make tumours more susceptible to immune attack.
The announcement comes at a time when the cancer immunotherapy market is expanding rapidly, with a growing number of combination therapies being explored. LAG-3 is an immune checkpoint receptor that negatively regulates T-cell activation, and its inhibition has shown promise in clinical trials. However, the development of small-molecule inhibitors for LAG-3 is still in early stages, and this collaboration could provide Onco with a first-mover advantage in this niche area.
For Onco-Innovations, this LOI represents a potential diversification of its pipeline beyond its current focus on DDR inhibitors. By adding an immunotherapy component, the company could address a broader range of solid tumours and potentially improve the efficacy of its existing candidates. The exclusive option would give Onco the right to evaluate the LAG-3 program before committing to a full acquisition, thereby reducing risk while preserving upside potential.
The move is also notable for the broader biotech sector, as it underscores the increasing interest in small-molecule immune checkpoint inhibitors. Most approved checkpoint inhibitors are monoclonal antibodies, but small molecules offer several advantages, including oral administration and lower production costs. If successful, this program could pave the way for a new class of cancer therapies that are more accessible to patients.
While the LOI is non-binding, it sets the stage for detailed due diligence and negotiation of a definitive agreement. The companies have not disclosed the financial terms of the potential deal, but the collaboration could involve milestone payments and royalties. Investors will be watching closely to see how this partnership evolves and whether it leads to a formal agreement.
For more information on this announcement, visit the full press release at https://ibn.fm/E63Ne. The latest news and updates on Onco-Innovations are available at https://ibn.fm/ONNVF.
